MGK_2 • 9h ago "Hope Rugo’s TNBC Nuke (UCSF): She ran leronlimab with carboplatin in 2019—stable disease at ASCO 2020. January 15 news says her 2025 TNBC basket trial’s live. Her bio whispers “CCR5 research”—leronlimab in there? It’s a sleeper atom bomb. Rugo’s a cancer titan; this could 3x CYDY in a flash."
"Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer*. She is also researching cognitive function in patients receiving chemotherapy for breast cancer* as well as ways to reduce toxicity from therapy .
Quote:Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy ."
Market Data 
Markets 
AI
